Meeting
2023 ASCO Annual Meeting
A phase I trial of diphencyprone for cutaneous neurofibromas in adult patients with neurofibromatosis type 1.
Authors
Dina Poplausky
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Dina Poplausky , Jade N Young , Brandon Block , Patricia Cabral , Ryan Rivera-Oyola , Yeriel Estrada , Giselle K Singer , Vicky K. Wong , Joel Correa Da Rosa , Rebecca M Brown , Nicholas Gulati
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Clinical Trial Registration Number
NCT05438290
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2678)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2678
Abstract #
TPS2678
Poster Bd #
512b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
First Author: Xiaojie Hu
Poster
2022 ASCO Annual Meeting
A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
First Author: Xiaojie Hu
Poster
2018 ASCO Annual Meeting
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).
First Author: Birgit Geoerger
Poster
2017 ASCO Annual Meeting
Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).
First Author: Lauren Hittson